Sumitomo Mitsui Trust Group
RXRX icon

Sumitomo Mitsui Trust Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.2M Buy
5,511,687
+92,466
+2% +$308K 0.01% 619
2026
Q1 		$16.6M Sell
5,419,221
-801,804
-13% -$3.1M 0.01% 637
2025
Q4 		$25.4M Sell
6,221,025
-1,244,833
-17% -$6.17M 0.01% 604
2025
Q3 		$36.4M Sell
7,465,858
-701,887
-9% -$3.69M 0.02% 553
2025
Q2 		$41.3M Sell
8,167,745
-311,539
-4% -$1.53M 0.03% 507
2025
Q1 		$44.9M Sell
8,479,284
-501,317
-6% -$3.65M 0.03% 469
2024
Q4 		$60.7M Sell
8,980,601
-786,127
-8% -$5.29M 0.04% 399
2024
Q3 		$64.4M Sell
9,766,728
-220,302
-2% -$1.58M 0.04% 388
2024
Q2 		$74.9M Sell
9,987,030
-375,773
-4% -$3.28M 0.06% 332
2024
Q1 		$103M Buy
10,362,803
+1,159,023
+13% +$12.9M 0.07% 286
2023
Q4 		$90.7M Buy
9,203,780
+5,680,656
+161% +$40.5M 0.07% 314
2023
Q3 		$27M Buy
3,523,124
+2,685,724
+321% +$26.8M 0.02% 623
2023
Q2 		$6.26M Buy
837,400
+335,423
+67% +$2.35M ﹤0.01% 820
2023
Q1 		$3.35M Buy
501,977
+47,455
+10% +$376K ﹤0.01% 866
2022
Q4 		$3.5M Sell
454,522
-36,218
-7% -$355K ﹤0.01% 877
2022
Q3 		$5.22M Buy
490,740
+90,839
+23% +$920K ﹤0.01% 842
2022
Q2 		$3.25M Buy
+399,901
New +$2.68M ﹤0.01% 904
2022
Q1 		– Sell
-368,994
Closed -$6.32M – 1230
2021
Q4 		$6.32M Sell
368,994
-40,200
-10% -$756K ﹤0.01% 817
2021
Q3 		$9.42M Buy
409,194
+195,586
+92% +$5.54M 0.01% 781
2021
Q2 		$7.8M Buy
+213,608
New +$6.32M ﹤0.01% 816

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sumitomo Mitsui Trust Group's RXRX Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group increased its Recursion Pharmaceuticals (RXRX) stake by 1.7% in Q2 2026, buying an estimated $308K and bringing the position to 5,511,687 shares worth $20.2M. The position accounts for 0.01% of the portfolio, ranked #619.

Sumitomo Mitsui Trust Group first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $103M in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 5,511,687 shares of Recursion Pharmaceuticals worth $20.2M as of Q2 2026.
  • Sumitomo Mitsui Trust Group bought 92,466 Recursion Pharmaceuticals shares in Q2 2026, an estimated $308K.
  • Recursion Pharmaceuticals made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #619 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Sumitomo Mitsui Trust Group's Recursion Pharmaceuticals position peaked at $103M in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.